tiprankstipranks
Adaptimmune Therapeutics (DE:473A)
MUNICH:473A
Germany Market

Adaptimmune Therapeutics (473A) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

473A Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Adaptimmune
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

473A Stock 12 Month Forecast

There Are No Analyst Ratings for DE:473A In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

473A Financial Forecast

473A Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

473A Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:473A
Barclays
Barclays
€0.4
Sell
3889.76%
Upside
Reiterated
08/14/25
Adaptimmune Therapeutics (ADAP) Gets a Sell from Barclays
Leerink Partners Analyst forecast on DE:473A
Leerink Partners
Leerink Partners
€0.1€0.08
Hold
680.61%
Upside
Reiterated
08/13/25
Hold Rating Maintained for Adaptimmune Therapeutics Amid Revenue Growth and Strategic Uncertainties
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:473A
Barclays
Barclays
€0.4
Sell
3889.76%
Upside
Reiterated
08/14/25
Adaptimmune Therapeutics (ADAP) Gets a Sell from Barclays
Leerink Partners Analyst forecast on DE:473A
Leerink Partners
Leerink Partners
€0.1€0.08
Hold
680.61%
Upside
Reiterated
08/13/25
Hold Rating Maintained for Adaptimmune Therapeutics Amid Revenue Growth and Strategic Uncertainties
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Adaptimmune Therapeutics

3 Months
Peter LawsonBarclays
Success Rate
8/12 ratings generated profit
67%
Average Return
+16.35%
Copying Peter Lawson's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +16.35% per trade.
1 Year
Peter LawsonBarclays
Success Rate
8/10 ratings generated profit
80%
Average Return
+47.62%
Copying Peter Lawson's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +47.62% per trade.
2 Years
Peter LawsonBarclays
Success Rate
8/9 ratings generated profit
89%
Average Return
+65.03%
Copying Peter Lawson's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +65.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

473A Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
0
0
In the current month, 473A has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 473A average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

473A Stock Forecast FAQ

What is DE:473A’s average 12-month price target, according to analysts?
Currently, no data Available
What is DE:473A’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:473A, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Adaptimmune Therapeutics a Buy, Sell or Hold?
      Currently, no data Available
      What is Adaptimmune Therapeutics’s share price target?
      Currently, no data Available
      What do analysts say about Adaptimmune Therapeutics?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Adaptimmune Therapeutics?
      To buy shares of DE:473A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.